CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology
Author: Benzinga Newsdesk | December 05, 2023 08:34am
CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced that it has entered into a Heads of Agreement (HOA) with CytoMed Therapeutics China Limited (CytoMed China), a company incorporated in Hong Kong and a Memorandum of Understanding (MOU) with BioNex Solutions Inc., 千尋生命科學.
Posted In: GDTC